Sam Lidman: Daily

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Space42 and Viasat's new venture, Equatys, aims to connect billions with a neutral, shared satellite network, challenging rivals like Starlink and AST.

At MWC 2026, TCL unveils a two-pronged attack with its eye-friendly Note A1 NXTPAPER for productivity and the immersive TAB A1 Plus for media.

emnify's SGP.32 eSIM solution promises to end physical SIM logistics, offering programmable, resilient, and vendor-independent connectivity for IoT.

Taiga Building Products posts a Q4 loss after a major asset write-down tied to the U.S. market, revealing surprising operational strength amid industry headwinds.

Once a volatile meme stock, AMTD Digital reports staggering financial growth. But can its diverse and complex empire sustain this incredible momentum?

The European real estate giant reports robust rental growth, deleverages with SEK 10.7B in asset sales, and secures a pivotal legal victory.

Banuba's new AI Talking Photo API promises to revolutionize video creation, but the rise of lifelike digital avatars also fuels a critical ethical debate.

Infrastructure software giant posts 11% revenue growth, outlines a bullish 2026 forecast, and doubles down on AI with key acquisitions.

On the war's fourth anniversary, Kyivstar's board, including Mike Pompeo, visited Kyiv, reaffirming a $1B investment and honoring resilient employees.

The therapy giant reports robust revenue growth and record patient visits, backed by major acquisitions and new 10-year hospital system alliances.

Canada's livestock producers who rent pastureland will see fairer support as AgriStability now covers feed costs, a key move for sector stability.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

The secure identity firm beat Wall Street estimates with accelerating revenue and record cash flow, signaling major growth and increased shareholder returns.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.

A Senate hearing highlights a growing national trend: using advanced tech to stop fraud and ensure billions in child care funds reach the families who need them.

A planned reverse merger for promising vaccine developer SVF Vaccines has collapsed after Nasdaq rejected the deal, leaving its lead investor scrambling.

With 80% of Indian diets lacking protein, the fast-food giant is serving up a science-backed solution. But can a burger truly bridge a national nutrition gap?

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.